Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients With Chronic Genotype 2 or 3 HCV Infection
Brief Summary: This study was to assess the safety and efficacy of sofosbuvir (GS-7977; PSI-7977) in combination with ribavirin (RBV) administered for 12 weeks compared with pegylated interferon (PEG)/RBV administered for 24 weeks in treatment-naive patients with Hepatitis C (HCV) genotype 2 or 3. Efficacy was assessed by the rate of sustained viral response (SVR) 12 weeks after the discontinuation of therapy (SVR12). This was a non-inferiority study, and if non-inferiority was demonstrated, the study was then allowed to test for superiority.


Options:
A: Arm Label: Group A: T12/PR48; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Arm Label: Group B: T12(DS)/PR48; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Arm Label: Group C: Pbo/PR48; Type: EXPERIMENTAL; Interventions: Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48 | Intervention Type: DRUG; Name: Peg-IFN-alfa-2a; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48
B: Arm Label: T12PR24 (eRVR+); Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon alfa-2a | Arm Label: T12PR48 (eRVR+); Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon alfa-2a | Arm Label: T12PR48 (eRVR-); Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon alfa-2a | Arm Label: Other; Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon alfa-2a | Intervention Type: DRUG; Name: telaprevir; Assigned to Arm(s): Other, T12PR24 (eRVR+), T12PR48 (eRVR+), T12PR48 (eRVR-) | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Other, T12PR24 (eRVR+), T12PR48 (eRVR+), T12PR48 (eRVR-) | Intervention Type: BIOLOGICAL; Name: peginterferon alfa-2a; Assigned to Arm(s): Other, T12PR24 (eRVR+), T12PR48 (eRVR+), T12PR48 (eRVR-)
C: Arm Label: Sofosbuvir+PEG+RBV; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Sofosbuvir+PEG+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Sofosbuvir+PEG+RBV | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): Sofosbuvir+PEG+RBV
D: Arm Label: Sofosbuvir+RBV; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV | Arm Label: PEG+RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEG, Drug: RBV | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Sofosbuvir+RBV | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): PEG+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): PEG+RBV, Sofosbuvir+RBV

Answer: D